scholarly journals Editorial: risk of loss of response to anti TNFα in patients with inflammatory bowel diseases – the longer the less? Authors' reply

2021 ◽  
Vol 55 (2) ◽  
pp. 246-246
Author(s):  
Johannes P. D. Schultheiss ◽  
Remi Mahmoud ◽  
Herma H. Fidder ◽  
Bas Oldenburg
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Loss Of Response ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals P387 Persistence of antibodies to infliximab for more than two months strongly predicts loss of response to infliximab in inflammatory bowel diseases

2014 ◽  
Vol 8 ◽  
pp. S226-S227 ◽  
Author(s):  
M. Leclerc ◽  
H. Marotte ◽  
S. Paul ◽  
E. Del Tedesco ◽  
P. Gonzalo ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Loss Of Response ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Sa1257 Persistence of Antibodies to Infliximab for More Than Two Months Predicts Loss of Response to Infliximab in Inflammatory Bowel Diseases

2014 ◽  
Vol 146 (5) ◽  
pp. S-245
Author(s):  
Manon Leclerc ◽  
Hubert Marotte ◽  
Stephane Paul ◽  
Emilie Del Tedesco ◽  
Jean Marc Phelip ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Loss Of Response ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Sa1981 Predictors of Loss of Response to Adalimumab Therapy; the Importance of Therapeutic Drug Monitoring in Inflammatory Bowel Diseases

2016 ◽  
Vol 150 (4) ◽  
pp. S423
Author(s):  
Zsuzsanna Kurti ◽  
Zsuzsanna Vegh ◽  
Petra A. Golovics ◽  
Krisztina Gecse ◽  
Lorant Gonczi ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Inflammatory Bowel Diseases ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Loss Of Response ◽  
Adalimumab Therapy ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals P436 Secondary loss of response to anti-TNF in inflammatory bowel diseases. Therapeutic drug monitoring. Utility in clinical practice

2017 ◽  
Vol 11 (suppl_1) ◽  
pp. S298-S298
Author(s):  
M. Jimenez ◽  
M. Sierra-Ausin ◽  
N. Cano ◽  
P. Suarez ◽  
M. Fernandez-Gundin ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Therapeutic Drug Monitoring ◽  
Inflammatory Bowel Diseases ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Secondary Loss ◽  
Loss Of Response ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals Vedolizumab in the treatment of inflammatory bowel diseases: whom and how?

2018 ◽  
pp. 44-49
Author(s):  
A. O. Golovenko ◽  
O. V. Golovenko
Keyword(s):  
Ulcerative Colitis ◽  
Clinical Trials ◽  
Clinical Practice ◽  
Inflammatory Bowel Diseases ◽  
Safety Profile ◽  
Actual Clinical Practice ◽  
Loss Of Response ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Available Information

The article is devoted to the use of vedolizumab, an α4β7 integrin antagonist, in the treatment of inflammatory bowel diseases (ulcerative colitis and Crohn’s disease). It presents the results of clinical trials of the drug and the experience of using vedolizumab in actual clinical practice. The latest available information about the drug’s safety profile is provided. The authors considered the practical aspects of therapy, such as determining the indications for treatment, tactics in loss of response, the need for a combination of vedolizumab with immunosuppressors, and the use of the drug in specific categories of patients.

scholarly journals ASSESSMENT OF LOSS OF RESPONSE TO INFLIXIMAB THERAPY IN INFLAMMATORY BOWEL DISEASES USING ANTIBODIES TO INFLIXIMAB AND TROUGH LEVELS

2013 ◽  
Vol 4 ◽  
Author(s):  
Guidi Luisa ◽  
Marzo Manuela ◽  
Andrisani Gianluca ◽  
Papa Alfredo ◽  
Felice Carla ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Infliximab Therapy ◽  
Loss Of Response ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Trough Levels

The STICC project: A population based study on the incidence of inflammatory bowel diseases in the state of Styria, Austria, from 1997–2007

2010 ◽  
Vol 48 (05) ◽  
Author(s):  
W Petritsch ◽  
S Fuchs ◽  
G Bachmaier ◽  
G Schwantzer ◽  
U Gratzer ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Population Based ◽  
The State ◽  
Population Based Study ◽  
Bowel Diseases ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document